PSMA and Beyond 2025 Conference

Viewing 1-20 of 35 articles

PSMA and Beyond 2025: CAR-T and Bispecific Antibodies Targeting PSMA

PSMA and Beyond 2025: Role of ADCs in Prostate Cancer

PSMA and Beyond 2025: Next Generation PSMA Radioligands

PSMA and Beyond 2025: PSMA-I&T vs PSMA-617: Is There a Difference?

PSMA and Beyond 2025: Role of PSMA Targeted Antibodies

PSMA and Beyond 2025: CA-IX in Renal Cell Cancer

PSMA and Beyond 2025: GRPR and Other Peptides for Targeting Prostate Cancer

PSMA and Beyond 2025: Keynote Lecture: Improving Outcomes with Combination Therapy

PSMA and Beyond 2025: Beyond PSMA in Prostate Cancer: STEAP1, DLL3, and CD46

PSMA and Beyond 2025: Role for Other Radionuclides: Tb161

PSMA and Beyond 2025: Opportunity for RLT in Bladder Cancer

PSMA and Beyond 2025: Management of Dry Mouth

PSMA and Beyond 2025: PSMA RLT in a Radiation Oncology Private Center

PSMA and Beyond 2025: PSMA RLT in a Medical Oncology Private Center

PSMA and Beyond 2025: Ac225 PSMA Experience

PSMA and Beyond 2025: 212Pb-PSMA vs 225Ac-PSMA: from Biology to Supply

PSMA and Beyond 2025: Impact of Clinical Guidelines on the Utilization of PSMA PET

PSMA and Beyond 2025: Incorporating PSMA PET into Clinical Trials

PSMA and Beyond 2025: Landscape of Approved PSMA Imaging Agents: Does It Matter?

PSMA and Beyond 2025: Moving into the Castration Sensitive Setting

1
2